-
Article
Triggered - does maternal COVID-19 program an exaggerated immune response in neonates?
The consequences of gestational coronavirus disease 2019(COVID-19) exposure on neonatal immunity are incompletely understood. While vertical transmission to the fetus is rare, maternal COVID-19 exposure can ad...
-
Article
Correction: Triggered - does maternal COVID-19 program an exaggerated immune response in neonates?
-
Article
Open AccessAutoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity
Increased inflammation caused by SARS-CoV-2 infection can lead to severe coronavirus disease 2019 (COVID-19) and long-term disease manifestations. The mechanisms of this variable long-term immune activation ar...
-
Article
Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
A suboptimal response to the 2-dose COVID-19 vaccine series in the immunocompromised population prompted recommendations for a 3rd primary dose. We aimed to determine the humoral and cellular immune response t...
-
Article
Open AccessThe cellular and immunological dynamics of early and transitional human milk
Human milk is essential for infant nutrition and immunity, providing protection against infections and other immune-mediated diseases during the lactation period and beyond in later childhood. Milk contains a ...
-
Article
Open AccessSingle-cell analysis of immune cell transcriptome during HIV-1 infection and therapy
Cellular immune responses are phenotypically and functionally perturbed during HIV-1 infection, with the majority of function restored upon antiretroviral therapy (ART). Despite ART, residual inflammation rema...
-
Article
Open AccessCross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination
SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has resulted in millions of deaths worldwide. Novel coronavirus infections in humans have steadily become more common. Understandi...
-
Article
Open AccessImmune cell residency in the nasal mucosa may partially explain respiratory disease severity across the age range
Previous studies focusing on the age disparity in COVID-19 severity have suggested that younger individuals mount a more robust innate immune response in the nasal mucosa after infection with SARS-CoV-2. Howev...
-
Article
Open AccessHumoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
The global pandemic of coronavirus disease 2019 (COVID-19) is caused by infection with the SARS-CoV-2 virus. Currently, there are three approved vaccines against SARS-CoV-2 in the USA, including two based on m...
-
Article
Cross-reactive antibody immunity against SARS-CoV-2 in children and adults
-
Article
Open AccessSingle cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy
Immunotherapy fails to cure most cancer patients. Preclinical studies indicate that radiotherapy synergizes with immunotherapy, promoting radiation-induced antitumor immunity. Most preclinical immunotherapy st...
-
Article
Open AccessImmune checkpoint modulation enhances HIV-1 antibody induction
Eliciting protective titers of HIV-1 broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development, but current vaccine strategies have yet to induce bnAbs in humans. Many bnAbs isolated from ...
-
Article
Open AccessHLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers
A paradigm shifting study demonstrated that induction of MHC class E and II-restricted CD8+ T cells was associated with the clearance of SIV infection in rhesus macaques. Another recent study highlighted the p...
-
Article
Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV
Antibodies are the primary correlate of protection for most licensed vaccines; however, their mechanisms of protection may vary, ranging from physical blockade to clearance via the recruitment of innate immuni...
-
Article
Open AccessA CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge
The envelope glycoprotein (Env) trimer ((gp120/gp41)3) mediates human immunodeficiency virus (HIV-1) entry into cells. The “closed,” antibody-resistant Env trimer is driven to more open conformations by binding t...
-
Article
Open AccessInitiation of HIV neutralizing B cell lineages with sequential envelope immunizations
A strategy for HIV-1 vaccine development is to define envelope (Env) evolution of broadly neutralizing antibodies (bnAbs) in infection and to recreate those events by vaccination. Here, we report host toleranc...
-
Article
Open AccessPentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we design an ALVAC/Pentavalent B/E/E/E/...
